UNDERSTANDING YOUR OPTIONS
What Is External Review?
A Fresh Set of Eyes
External review means your case is evaluated by independent medical experts—not your insurance company. Under the Affordable Care Act, you have the legal right to request this review after your internal appeal is denied.[1]
When your insurer denies your Wegovy coverage and upholds that decision on internal appeal, you're not out of options. External review takes your case outside the insurance company entirely.
Internal Appeal vs. External Review
| Feature | Internal Appeal | External Review |
|---|---|---|
| Who Reviews | Insurance company employees | Independent Review Organization (IRO) |
| Timeline | 30 days for services not yet received; 60 days for services already received (faster if urgent) | 45 days (72 hrs expedited) |
| Success Rate | ~44% | 40-60%+ |
| Binding? | No—insurer can deny again | Yes—insurer must comply |
| Cost | Free | Free (federal) or max $25 (state) |
The key difference: external review decisions are binding. If the independent reviewer rules in your favor, your insurance company is legally required to cover your medication.[1]
For information on internal appeals, see our Wegovy appeals overview or specific guides for medical necessity denials.
EXTERNAL REVIEW REQUIREMENTS
When Are You Eligible?
Under the ACA, you can request external review when:[2]
Your internal appeal was denied
After your insurance company issues a "final internal adverse benefit determination" (their final denial on internal appeal), you have 4 months to request external review (some states allow longer).
Your case is urgent (expedited)
For urgent health situations, you can file for external review at the same time as your internal appeal. Qualifying situations include:
- Your health condition could seriously deteriorate without treatment
- Waiting would jeopardize your ability to regain maximum function
- You're experiencing severe pain that requires immediate treatment
Expedited reviews are decided within 72 hours or less.
The denial involves medical judgment
External review is available when your insurer denies coverage based on:
- Medical necessity — "Wegovy isn't medically necessary for your condition"
- Experimental/investigational — "This treatment is considered experimental"
- Clinical judgment — Any decision where medical opinion is involved
Note: Denials based purely on contractual exclusions (like "weight loss medications excluded from benefits") may not qualify for external review.
Your coverage was cancelled
If your insurer cancels your coverage based on claims that you gave false or incomplete information when you applied, you have the right to external review of that decision.
Don't Miss Your Deadline
You have 4 months from the date of your final internal denial to request external review. This deadline is strict—if you miss it, you may lose your right to independent review.[1]
STEP-BY-STEP PROCESS
How to Request External Review
Follow these steps to file for external review of your Wegovy denial:
Get Your Final Denial Letter
Request your "final internal adverse benefit determination" in writing from your insurer. This letter should include:
- The specific reason for denial
- Information about your external review rights
- Instructions on how to request external review
- The deadline to file (usually 4 months from this letter)
Determine Your Review Process
Your external review process depends on your plan type and state:
- State process: Most states have their own external review programs (CA, NY, etc.)
- Federal process: Some states use the HHS-administered federal process through MAXIMUS (TX, FL, GA, PA, WI, AL)
Check your denial letter or call your state insurance department to confirm which process applies to you.
Gather Your Documentation
Collect everything that supports your case:
- Final denial letter from your insurer
- All correspondence from your internal appeal
- Medical records documenting your condition
- Letter of Medical Necessity from your doctor
- Clinical evidence (STEP trial data, SELECT cardiovascular data, guidelines)
- Documentation of prior weight loss attempts
File Your External Review Request
Federal process (MAXIMUS):
- Online portal: externalappeal.cms.gov
- Phone: 1-888-866-6205
- Mail: MAXIMUS Federal Services, 3750 Monroe Avenue, Suite 705, Pittsford, NY 14534
State process: Contact your state insurance department for specific filing instructions.
Consider Provider Assistance
You can appoint a representative (like your doctor) to file on your behalf. Many providers will:
- Submit the external review request for you
- Write a letter of support with clinical justification
- Provide additional medical documentation
Wait for the Decision
Within 5 business days, you'll receive confirmation that your request was received. Then:
- Standard review: Decision within 45 days
- Expedited review: Decision within 72 hours (or less for urgent cases)
The decision is final and binding on your insurer.[1]
Your GLP-1 coverage,
denied approved
External review requires strong documentation. Honest Care can help you build a compelling case.
Need help with your external review?
Get Started FreeSTRENGTHENING YOUR CASE
What Reviewers Look For
Independent reviewers are medical professionals who evaluate your case based on clinical evidence and medical standards—not cost considerations. Here's what makes a strong external review case for Wegovy:
Documentation Checklist
What to Include in Your External Review
- Final denial letter from your insurer
- All internal appeal correspondence
- Medical records showing obesity diagnosis (BMI ≥30 or ≥27 with comorbidities)
- Comorbidity documentation with ICD-10 codes (type 2 diabetes, hypertension, OSA, cardiovascular disease, etc.)
- Prior treatment history (diet programs, exercise, other medications tried)
- Letter of Medical Necessity from your prescribing physician
- Clinical evidence (STEP trials, SELECT trial, FDA approval, professional guidelines)
Clinical Evidence That Supports Wegovy
Include these key data points in your external review submission:
| Evidence Source | Key Finding | Why It Matters |
|---|---|---|
| STEP 1 Trial | 14.9% weight loss at 68 weeks | Far exceeds 3-5% from lifestyle alone |
| SELECT Trial | 20% reduction in major cardiovascular events | Demonstrates life-saving benefits—FDA-approved indication |
| FDA Obesity Approval (2021) | Approved for chronic weight management | Not experimental or investigational |
| FDA CV Approval (March 8, 2024 (Wegovy injection)) | First weight-loss drug approved to reduce cardiovascular risk (adults with established cardiovascular disease and either obesity or overweight) | Large cardiovascular outcomes trial (SELECT) |
| AMA Recognition (2013) | Obesity classified as disease | Treatment is medical, not cosmetic |
How to Present Your Case
Sample Language for External Review
Opening:
"I am requesting external review of [Insurance Company]'s denial of coverage for Wegovy (semaglutide). My internal appeal was denied on [date], and I believe this decision does not reflect current medical standards or the clinical evidence supporting this medication's necessity for my condition."
Medical necessity argument:
"Obesity is recognized as a chronic, relapsing disease by the American Medical Association (2013), World Health Organization, and CDC. My documented BMI of [X] kg/m² and comorbidities including [list conditions] meet the FDA-approved criteria for Wegovy treatment. Clinical trials (STEP 1) demonstrate 14.9% weight loss with semaglutide, significantly exceeding the 3-5% typically achieved through lifestyle modification alone."
Cardiovascular benefit argument:
"Wegovy is the first weight loss medication FDA-approved to reduce cardiovascular risk in adults with established cardiovascular disease and either obesity or overweight. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (heart attack, stroke, CV death). Given my established cardiovascular disease, this medication offers unique protective benefits beyond weight loss."
Prior treatment failure:
"I have attempted multiple weight management approaches including [diet programs, exercise regimens, other medications], as documented in my medical records. These interventions did not produce sustained weight loss, demonstrating the medical necessity of pharmacological treatment."
Pro tip: Reference the exact language from your insurer's denial and directly counter each point with clinical evidence.
WHAT TO EXPECT
Timelines & Success Rates
External Review Timeline
| Stage | Standard Review | Expedited Review |
|---|---|---|
| Filing deadline | 4 months from final denial | Same (can file with internal appeal) |
| Preliminary review | 5 business days | Immediate |
| Final decision | 45 days maximum | 72 hours or less |
Success Rate Statistics
External Reviews Have Higher Success Rates
External review success rates range from 40-60% depending on the case type and jurisdiction. In California, the Department of Managed Health Care reports that 60-80% of denials taken to Independent Medical Review are reversed.[3]
Key statistics from published research:
- Internal appeals: ~44% success rate for patients who appeal (KFF)[4]
- External reviews (general): ~27% overturn rate for cases reaching this stage[5]
- California IMR: 60-80% of denials reversed (National Nurses United)[3]
- Medicare Advantage external: 10-27% overturned (HHS OIG)[6]
The Appeal Gap
Less than 1% of denied claims are ever appealed—despite the fact that nearly half succeed when patients do appeal. Don't be part of the 99% who give up.[4]
WHICH APPLIES TO YOU
State vs Federal Programs
Your external review process depends on your state and plan type. Most states have their own external review programs, but some use the federal HHS process.[7]
State vs. Federal External Review
State programs apply if your state has an external review process that meets or exceeds ACA standards. Many state programs offer stronger consumer protections.
Federal program (MAXIMUS) applies in states without compliant programs: Alabama, Florida, Georgia, Pennsylvania, Texas, and Wisconsin—plus self-funded employer plans in any state.
State External Review Examples
| State | Program | Key Features |
|---|---|---|
| California | DMHC Independent Medical Review | 60-80% overturn rate; specialist reviewers required; SB 1120 prohibits AI-only denials |
| New York | DFS External Appeal | Strong protections; automatic external review available; specialist reviewer required |
| Texas | Federal (MAXIMUS) | Uses HHS process; 72-hour expedited option; free to patients |
| Florida | Federal (MAXIMUS) | Uses HHS process; ACA minimum protections apply |
How to find your state's process:
- Check your final denial letter—it should include external review instructions
- Visit your state insurance department website
- Call your state insurance commissioner's office
- Or use the KFF state external review lookup
EXTERNAL REVIEW FOR WEGOVY
Frequently Asked Questions
External review is an independent evaluation of your insurance denial by medical professionals who don't work for your insurer. Under the Affordable Care Act (ACA), you have the legal right to request external review after your internal appeal is denied. An Independent Review Organization (IRO) examines your case based on clinical evidence and medical standards, and their decision is binding on your insurance company.
You can request external review after your insurance company issues a final internal denial. You have 4 months from the date of that final denial to file (some states allow longer). For urgent health situations, you can request expedited external review at the same time as your internal appeal.
External review success rates vary but are generally higher than internal appeals. Studies show rates of 40-60% for cases that reach external review. In California, the Department of Managed Health Care reports that 60-80% of denials taken to Independent Medical Review are reversed. However, less than 1% of denied claims are ever appealed, despite these relatively high success rates.
Standard external reviews must be decided within 45 days of filing. For urgent or expedited cases, decisions must come within 72 hours or less. You'll receive confirmation that your request was received within 5 business days.
The HHS-administered federal external review process is free. State external review programs may charge a fee, but it cannot exceed $25 per external review request.
Most states have their own external review programs that meet or exceed ACA standards. Some states (Alabama, Florida, Georgia, Pennsylvania, Texas, Wisconsin) use the federal HHS process administered by MAXIMUS. Self-funded employer plans typically use the federal process regardless of state. Your denial letter should indicate which process applies to you.
Yes. Under the ACA, external review decisions are binding on your insurance company. If the independent reviewer rules in your favor, your insurer is legally required to cover the medication or service.
Yes. You can appoint a representative, such as your doctor or another healthcare provider, to file the external review on your behalf. Many providers will also write letters of support and provide additional documentation to strengthen your case.
It can, if you have established cardiovascular disease. Wegovy is the first weight-loss medication FDA-approved to reduce cardiovascular risk in adults with established cardiovascular disease and either obesity or overweight (injection: March 8, 2024 (Wegovy injection); tablets: December 22, 2025 (Wegovy tablets)). The SELECT trial showed a 20% reduction in heart attacks, strokes, and cardiovascular death. If your denial cited "cosmetic" or "not medically necessary," this approval is evidence that Wegovy treats a medical condition, not a cosmetic one.
YOUR PATH FORWARD
What's Next
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get startedWHAT'S CHANGING
External Review: 2026 Outlook
2026: State External Review Reforms Expanding
Several states are strengthening their independent medical review processes. California's SB 1120 now prohibits AI-only denials, requiring physician oversight—a model other states are considering. These reforms may improve external review success rates as more cases receive thorough human evaluation.
CMS Prior Authorization Rule Impact
The CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F) takes effect in 2026 with transparency requirements:
- Faster PA decisions: From January 1, 2026, Medicare Advantage, Medicaid and CHIP must decide medical prior authorizations within 7 days (72 hours if urgent); the rule excludes drugs
- Denial reason disclosure: Insurers must explain specific reasons
- Better documentation: Clearer criteria may strengthen external review cases
These requirements apply to Medicare Advantage, Medicaid and CHIP medical-service decisions; because the rule excludes drugs, they don't apply to GLP-1 prescription denials.
If External Review Fails: NovoCare Options
For patients who exhaust all appeal options, Novo Nordisk's NovoCare program offers savings options:
- Savings Card: Eligible patients may pay as little as $0 for a 28-day supply (with commercial insurance)
- Patient Assistance Program: Free medication for qualifying uninsured patients
- Coverage Support: Help navigating insurance requirements
Visit novocare.com/wegovy for current programs and eligibility.
Wegovy's Cardiovascular Advantage
If you have established cardiovascular disease and either obesity or overweight, Wegovy's FDA-approved cardiovascular indication (injection: March 8, 2024 (Wegovy injection); tablets: December 22, 2025 (Wegovy tablets)) can strengthen an external review case. Wegovy is the first weight-loss medication approved to reduce heart attack, stroke, and cardiovascular death risk in that population.
If your denial cited "cosmetic" or "not medically necessary," the SELECT trial data (20% MACE reduction) provides strong counter-evidence that Wegovy is a life-saving medication, not a cosmetic treatment.
References
- HealthCare.gov. "External Review." U.S. Department of Health & Human Services. healthcare.gov
- Centers for Medicare & Medicaid Services. "HHS-Administered Federal External Review Process for Health Insurance Coverage." cms.gov
- National Nurses United. (2024). "60-80% of Insurance Denials Overturned When Taken to Independent Medical Review." nationalnursesunited.org
- Kaiser Family Foundation. (2023). "Claims Denials and Appeals in ACA Marketplace Plans." kff.org
- American Medical Association. (2023). "Over 80% of Prior Auth Appeals Succeed—Why Aren't There More?" ama-assn.org
- U.S. Department of Health and Human Services Office of Inspector General. (2018). "Medicare Advantage Appeal Outcomes and Audit Findings Raise Concerns About Service and Payment Denials." oig.hhs.gov
- Kaiser Family Foundation. "State External Appeals Review Processes." kff.org
- Wilding JPH, et al. (2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. STEP 1 trial. PubMed
- Lincoff AM, et al. (2023). "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." N Engl J Med. SELECT trial. PubMed
- U.S. Food and Drug Administration. (2024). "FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight." fda.gov
- American Medical Association. (2013). "AMA Adopts New Policies on Second Day of Voting at Annual Meeting." Resolution 420 recognizing obesity as a disease. ama-assn.org
- Counterforce Health. (2024). "Insurance Denial Statistics: Why 80% of Appeals Succeed (But Only 1% Try)." counterforcehealth.org
Last updated October 6, 2026 · Key facts verified October 2, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.